Retinoid composition having enhanced bioavailability and percutaneous absorption
AssigneeNeutrogena Corporation
InventorsRichard A. Scott, Mitchell S. Wortzman, Eric Jungermann
Life of this patent
Estimating the term…
Abstract
A new and improved topically applied pharmaceutical preparation for the treatment of acne and an improved vehicle for delivering the active ingredients thereof to the human skin in a manner whereby the bioavailability and percutaneous absorption of the active ingredient is remarkably enhanced. The vehicle comprises a volatile silicone, a fatty alcohol having from 12-22 carbon atoms, retinoids selected from the group consisting of tretinoin (all-trans retinoic acid) and isotretinoin (13-cis retinoic acid); and such preservatives or emulsifying agents as may be warranted.
Claims11
A pharmaceutical preparation having enhanced bioavailability and percutaneous absorption comprising a mixture containing from about 20% up to about 40% (w/w) fatty alcohol having 12 to 22 carbon atoms or mixtures thereof;
- from about 30% up to about 60% (w/w) of a volatile silicone;
- from about 0.01% up to about 10% (w/w) of retinoids selected from the group consisting of tretinoin (all-trans retinoic acid) and isotretinoin (13-cis retinoic acid);
- and from about 1% to about 10% (w/w) of an ingredient selected from the group consisting of preservative, an emulsifier or a mixture thereof.
A pharmaceutical preparation for the treatment of acne consisting from about 0.01% up to about 10% (w/w) of 13-cis retinoic acid as its essential ingredient, said ingredient dispersed throughout a semi-solid vehicle having from about 20% up to about 40% (w/w) stearyl and cetyl alcohol;
- from about 30% up to about 60% (w/w) of a volatile silicone;
- and from about 1% to about 10% (w/w) of an ingredient selected from the group consisting of preservative, an emulsifier or a mixture thereof.
Dependencies are inferred from the claim text.